Novocure to Participate in 35th Annual Piper Sandler Healthcare Conference
2023年11月21日 - 9:00PM
ビジネスワイヤ(英語)
Novocure (NASDAQ: NVCR) announced today that management will
participate in the 35th Annual Piper Sandler Healthcare Conference
on Wednesday, November 29, 2023. William Doyle, Novocure’s
Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial
Officer, will take part in a fireside chat at 3:30 p.m. EST, as
well as one-on-one meetings with investors throughout the
event.
Live audio webcasts of these presentations can be accessed from
the Investor Relations page of Novocure’s website,
www.novocure.com/investor-relations, and will be available for
replay for at least 14 days following the event.
Novocure’s corporate presentation is updated periodically, and
the current presentation can be accessed from the Investor
Relations page of Novocure’s website,
www.novocure.com/investor-relations. Novocure has used, and intends
to continue to use, its Investor Relations website as a means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical study progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231121821674/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
過去 株価チャート
から 5 2024 まで 6 2024
NovoCure (NASDAQ:NVCR)
過去 株価チャート
から 6 2023 まで 6 2024